Business Builders in Healthcare Pharma Medical Devices Biotech Consumer Health Healthcare

The Plexus Edge

Plexus’ clients come to us to discuss their strategic objectives and augment their capabilities to manage long and time-consuming transactions that would direct internal resources away from important activities. The following factors are what determines the Plexus’ advantage.

Network

We interact with key decision makers at healthcare companies of all sizes worldwide on a daily basis to discuss our broad portfolio of projects. We know them and they know Plexus.

Credibility

Companies react to Plexus’ projects as they trust the “reverse due diligence” we perform to assess the validity of a project.

Transaction Excellence

We bring structure into opportunistic and unstructured corporate and business development activities to achieve objectives quickly and with the best possible outcome offered by the market at a given time.

A Global Presence

Plexus industry professionals are conveniently located in the United States, Europe and Asia-Pacific markets, enabling Plexus to benefit its clients with both local knowledge and global reach.

By the Numbers

EU- Related Transactions Closed

Japan- Related Assigments Earned

US- Related Transactions Closed

Transactions Completed

Results

Divested Cinfa Biotech to Mundipharma

Sale of oncology biosimilar development company with late-stage product.

Divested J&J rights to OTC brands to Trimb Healthcare

Sale of a portfolio of antifungal OTC products.

Divested Novartis CH rights to Habitrol® to Dr. Reddy’s

FTC-mandated divestment of nicotine patch to complete big asset swap.

Our Clients

Plexus Ventures has worked with a wide range of clients across the Healthcare spectrum: pharma, consumer healthcare, biotech and
medtech companies as well as a variety of investor groups. These are some of our current partners.

News & Events

Plexus Ventures Assists Glenmark Pharmaceuticals to Out-License Ryaltris™ Nasal Spray to Menarini for numerous markets throughout Europe

January 11, 2021 – Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Glenmark Pharmaceuticals.

Plexus Ventures advises Cinfa Group in PLG’s “Deal of the Year”

March 26, 2019 – London, England – The Pharmaceutical Licensing Group, whose mission is promote and support excellence in deal making across the healthcare industry, recently awarded Mundipharma International its inaugural “PLG Deal of the Year” for its acquisition of Cinfa Biotech.

Plexus Ventures Assists Glenmark Pharmaceuticals to Divest a CNS Product Portfolio and Commercial Team in Poland to Neuraxpharm

April 7, 2020 – Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the completion of a divestiture project on behalf of its client, Glenmark Pharmaceuticals Ltd. Plexus Ventures advised Glenmark on the sale of a CNS product portfolio and sales team to Neuraxpharm.

Keep in Touch

Want to find out more about what Plexus Ventures can do for you?  Drop us a line or join our newsletter.  We look forward to hearing from you!